Introduction {#s1}
============

Acetaminophen (APAP) is a widely used over-the-counter antipyretic and analgesic drug ([@B27]). Although it was considered as a safe drug, APAP overdosage can lead to hepatocellular necrosis and acute liver injury ([@B34]; [@B27]).

The majority of APAP is metabolized by conjugating enzymes UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) in the liver to nontoxic compounds, followed by renal and biliary excretion ([@B46]). Less than 10% of APAP is bioactivated by phase I cytochrome P450 (CYP) enzymes such as CYP1A2, CYP2E1, and CYP3A4 into reactive intermediate metabolite N-acetyl-p-benzoquinone-imine (NAPQI), which causes acute liver injury ([@B42]; [@B39]). NAPQI is detoxified by glutathione (GSH) to form a hazard-free metabolite ([@B3]). With APAP overdose, GSH is depleted, and as a result, NAPQI accumulates and binds to proteins and cause oxidative stress and the activation of c-Jun-NH~2~-terminal kinase (JNK) in the liver ([@B34]). JNK activation could trigger inflammation and recruitment of monocytes and neutrophils ([@B44]).

The 5-lipoxygenase (5-LO) pathway plays a significant role in the pathophysiology of APAP-induced liver inflammation and injury ([@B16]; [@B36]). Overdose of APAP was thought to upregulate 5-LO ([@B41]), resulting in increasing cysteinyl leukotrienes (CysLTs) secretion ([@B16]). Cysteinyl leukotriene receptor 1 (Cysltr1), a receptor for CysLTs, mediated various disease in humans as well as animal models. Previous reports indicated that the expression of Cysltr1 is upregulated in adenoid hypertrophy ([@B12]). Activation of Cysltr1 stimulates JNK phosphorylation ([@B28]), leading to the trigger of inflammation ([@B26]). Knockout of Cysltr1 prevents mice from irritant-induced asthma ([@B33]) and also reduces colitis-associated colon cancer ([@B35]).

Montelukast, as a selective inhibitor of Cysltr1, is clinically used for the prevention and long-term treatment of asthma ([@B30]). Several studies investigated that montelukast has an antioxidant effect in intestinal ischemia--reperfusion injury ([@B45]) and also reduces cardiac damage ([@B23]). The beneficial effects of montelukast have also been reported in various experimental models of liver injury ([@B9]; [@B15]). However, the mechanism of montelukast in APAP-induced hepatotoxicity remains unknown. Under the light of this information, we investigated whether the pharmacological inhibition of Cysltr1 by montelukast in mice could protect against APAP-induced hepatotoxicity.

Materials and Methods {#s2}
=====================

Chemicals and Reagents {#s2_1}
----------------------

APAP and dimethylsulfoxide (DMSO) was purchased from Sigma-Aldrich (St. Louis, USA). Montelukast and zafirlukast were purchased from meilunbio (Dalian, China). GSH/glutathionedisulfide(GSSG)assaykit was obtained from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The lactate dehydrogenase (LDH) cytotoxicity assay kit and the mitochondrial membrane potential assay kit with JC-1 were offered by the Beyotime Institute of Biotechnology (Shanghai, China). Primary antibodies according Cysltr1 and β-actin were purchased from Abclonal (Wuhan, China), and the secondary antibody was purchased from Jackson ImmunoResearch (PA, USA).

Animals {#s2_2}
-------

This study used 8-week-old C57BL/6J mice (22--25 g), which were randomly selected for this experimental study. The acute hepatic injury was induced by oral administration of APAP (200 mg/kg) before 16 h fasting as described ([@B37]; [@B36]). For therapeutic experiment, a dose of 3 mg/kg ([@B14]) of montelukast was prepared in a 0.5% carboxy methyl cellulose. Mice were gavaged in a volume of 100 μl at 1 h after APAP administration. Mice were killed by CO~2~ at 12 h after APAP administration, and blood and liver tissue were harvested for histology. All mice in experiment were housed at West China Hospital, Sichuan University in accordance with the guidelines of the animal care utilization committee of the institute. Food and water were made freely available to the mice, except where otherwise state.

Serum Isolation and Alanine Transaminase and Aspartate Aminotransferase Detection {#s2_3}
---------------------------------------------------------------------------------

Blood was placed at 4°C for 1 h, then centrifuged at 3,000×*g* for 10 min. The serum was collected from the supernatant and was separately preserved at −80°C. Serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were detected using commercial assay kits (BioSino Bio-Technology & Science Inc.).

H&E Staining {#s2_4}
------------

The smallest lobe of the livers was removed and immediately fixed in 10% neutral-buffered formalin and embedded in paraffin, sectioned at 4 μm. For H&E staining, liver sections were stained with hematoxylin and eosin. Samples were visualized under a light microscope (Nikon, Japan).

Hepatic GSH/GSSG Detection {#s2_5}
--------------------------

Mice were killed at different time points after administration of APAP. Livers were isolated and immediately removed surface blood in saline, then homogenized in 5% trichloroacetic acid, then centrifuged at 3,500 rpm for 10 min. The supernatant was used to detect liver GSH/GSSG level by hepatic GSH/GSSG assay kit (Nanjing Jiancheng Bioengineering Institute, China).

Detection of Liver H~2~O~2~ Level and Thiobarbituric Acid Reactive Substances Production {#s2_6}
----------------------------------------------------------------------------------------

H~2~O~2~ level and thiobarbituric acid reactive substances (TBARS) in liver were measured as described ([@B36]).

Isolation and Treatment of Primary Mouse Hepatocytes {#s2_7}
----------------------------------------------------

Hepatocytes were isolated from 6-week-old C57 BL/6J mice and cultured as described ([@B24]; [@B11]). Montelukast was dissolved in DMSO, and DMSO was used a control. APAP was dissolved in high-glucose Dulbecco's modified Eagle's medium, which was supplemented with 2% fetal bovine serum. For therapeutic experiment, primary hepatocytes were pretreated with montelukast (1, 5, and 10 μM) or vehicle (0.02% DMSO) 1 h before APAP (2.5 mM) administration ([@B11]).

Cell Death {#s2_8}
----------

Cell death was measured using the LDH cytotoxicity assay kit (Beyotime, China) and the mitochondrial membrane potential assay kit (Beyotime, China) according to the manufacturers' recommendations. For the LDH release detection, Triton X-100, 1% (*w*/*v*), was used as a positive control. The percentage of LDH released was calculated as a ratio of the positive control LDH released ([@B11]). For the mitochondrial membrane potential detection, the cells were incubated with 5 mg/L JC-1 dye for 30 min at 37°C in the dark and washed twice with the dye buffer. Then, the cells were quickly subjected to a fluorescence microscope for captured red or green fluorescence ([@B6]).

RT-PCR Analysis {#s2_9}
---------------

Total liver RNA and cellular RNA were extracted using the Trizol Reagent (Invitrogen, Carlsbad, CA), and 1,000 ng of RNA was reverse transcribed to complementary DNA using a PrimeScript RT reagent Kit (Takara RR037A). Quantitative, real-time PCR was performed on the CFX96 real-time system (Biorad) using either SYBR Green Mix (Biorad). All of the primers used with SYBR green were designed to span at least one exon to minimize the possibility of nonspecific amplification from the genomic DNA. The expression of *18s* gene was used as a housekeeping gene to normalize data. Specific primer sequences are in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. Relative messenger RNA (mRNA) expression was quantified using the comparative CT (Ct) method and expressed as 2\^ (−∆∆Ct). Amplification specificity was evaluated by determining the product melting curve. Results are expressed as indicated in the figure legends. The following program was used: one step at 95°C for 2 min, 40 cycles of denaturation at 95°C for 30 s, and annealing and elongation at 60°C for 45 s.

Western Blotting {#s2_10}
----------------

Western blotting analyses were performed with protein extracts from liver homogenates (50 μg) using anti-p-ERK (1:2,000 dilution, Santa Cruz), anti-ERK (1:2,000 dilution, Santa Cruz), anti-p-JNK (1:1,000 dilution, CST), and anti-JNK (1:1,000 dilution, CST) antibodies. Immunoreactive bands were visualized on nitrocellulose membranes using alkaline phosphatase-conjugated antimouse or rabbit antibody and the Odyssey detection system (LI-COR, USA).

Statistical Analysis {#s2_11}
--------------------

Experiments were repeated at least three times with similar results. Quantitative results are expressed as the mean ± SEM. Statistical significance was determined by Student's unpaired two-tailed *t* test or one-way ANOVA multiple comparison test. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

APAP Induced Cysltr1 Expression Both *In Vivo* and *In Vitro* {#s3_1}
-------------------------------------------------------------

To examined whether APAP affected the expression of *Cysltr1*, C57 BL/6J mice underwent gavage with saline or APAP (200 mg/kg) after 16 h fasting. As expected, compared to saline treatment, acute APAP treatment induced liver damage ([**Figures 1A, B**](#f1){ref-type="fig"}). The mRNA and protein levels of *Cysltr1* were significantly upregulated in APAP-treated mice liver compared with vehicle group ([**Figures 1C--E**](#f1){ref-type="fig"}). In contrast, *Blt1* (LTB~4~ receptor 1) was slightly decreased after APAP treatment ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). APAP did not affect the expression of other leukotriene receptors such as *Blt2* and *Cysltr2* ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}).

![Acute acetaminophen (APAP) treatment upregulated *Cysltr1* expression *in vivo*. C57BL/6J mice fasted overnight, then were orally administered with saline or APAP (200 mg/kg) for 12 h. Data are mean ± SEM, *n* = 5 for saline group, *n* = 6 for APAP group. **(A)** Detection of serum alanine transaminase (ALT) and aspartate aminotransferase (AST). **(B)** H&E staining for livers from saline or APAP-treated mice. APAP-induced centrilobular necrosis was indicated by dotted line. **(C)** Real-time PCR analysis of hepatic messenger RNA (mRNA) expression of *Cysltr1*. **(D)** Western blot analysis of Cysltr1. **(E)** Quantification of Cysltr1 to β-actin. Data are mean ± SEM, *n* = 5, \**p* \< 0.05.](fphar-10-01070-g001){#f1}

We then isolated primary hepatocytes from C57/BL6J mice and assessed the mRNA and protein levels of *Cysltr1* after APAP administration *in vitro*. Similarly, the mRNA and protein level of *Cysltr1* were increased in APAP-treated hepatocytes compared with the vehicle group ([**Supplementary Figures 2A, C, D**](#SM1){ref-type="supplementary-material"}). However, the expression of *Blt1*, *Blt2*, and *Cysltr2* did not change after APAP administration ([**Supplementary Figures 2A, B**](#SM1){ref-type="supplementary-material"}).

Pharmacological Inhibition of Cysltr1 Prevented Acetaminophen-Induced Liver Injury {#s3_2}
----------------------------------------------------------------------------------

The increased expression of *Cysltr1* in APAP overdose-treated mouse liver prompted us to determine whether pharmacological inhibition of Cysltr1 would affect APAP-induced liver toxicity. C57BL/6J mice were treated with vehicle or the Cystlr1 antagonist, montelukast (3 mg/kg), 1 h after saline or APAP administration ([**Figure 2A**](#f2){ref-type="fig"}). Mice were killed 12 h after saline or APAP treatment, and blood and liver tissues were harvested. Montelukast treatment significantly decreased serum levels of ALT and AST ([**Figures 2B, C**](#f2){ref-type="fig"}) and alleviated liver damage as indicated by H&E staining in APAP-treated groups ([**Figures 2D, E**](#f2){ref-type="fig"}). Montelukast has no effect on saline-treated groups ([**Figures 2B--E**](#f2){ref-type="fig"}). These results suggested that inhibition of Cysltr1 protected mice from APAP-induced liver injury.

![Pharmacological inhibition of Cysltr1 protected against APAP-induced hepatotoxicity. **(A)**. Schedule of montelukast administration in APAP-overdose mice. Montelukast (3 mg/kg) or vehicle were administered 1 h after APAP treatment. At 12 h after APAP administration, mice were killed, and blood and liver tissues were collected. Serum levels of ALT **(B)** and AST **(C)**. **(D)** H&E staining of liver sections from APAP- or saline-treated mice. APAP-induced centrilobular necrosis was indicated by dotted line. **(E)** Quantification of liver necrosis area. Data are mean ± SEM, *n* = 5 for saline groups, *n* = 7 for APAP groups, \*\**p* \< 0.01.](fphar-10-01070-g002){#f2}

Montelukast Treatment Did Not Alter APAP Phase I/II Enzymes and Hepatic Transporters {#s3_3}
------------------------------------------------------------------------------------

Resistance to APAP toxicity in montelukast-treated mice led us to speculate that pharmacological inhibition of Cysltr1 may alter the formation of toxicity-induced metabolites and/or promote APAP clearance. To investigate whether montelukast administration affected APAP metabolism, we first measured phase I enzymes, which are responsible for the formation of toxic APAP metabolites. However, the expression of *Cyp1a2*, *Cyp2e1*, and *Cyp3a11* in livers were nearly comparable between montelukast-treated and vehicle group ([**Supplementary Figures 3A--C**](#SM1){ref-type="supplementary-material"}). Phase II enzymes were known to detoxify APAP. However, the expression of UDP-glucuronosyltransferase 1A1 (*Ugt1a1*) and sulfotransferase 2A1 (*Sult2a1*) did not change in montelukast-treated mice ([**Supplementary Figures 3D, E**](#SM1){ref-type="supplementary-material"}). Transporters were also associated with APAP-induced acute liver damage. However, montelukast administration did not alter the expression of transporters ([**Supplementary Figures 4A--C**](#SM1){ref-type="supplementary-material"}).

Montelukast Treatment Upregulated Hepatic GSH Level and Gstα2 Expression. {#s3_4}
-------------------------------------------------------------------------

GSH plays a critical role in detoxifying the reactive intermediate of APAP ([@B34]). With overdoses of APAP administration, hepatic GSH/GSSG level was markedly depleted in the vehicle group at 3 h and recovered at 12 h ([**Figure 3A**](#f3){ref-type="fig"}). However, hepatic GSH/GSSG level was higher in montelukast-treated mice at 3 h ([**Figure 3A**](#f3){ref-type="fig"}). There was no difference in hepatic GSH/GSSG levels between vehicle and montelukast-treated groups at 12 h after APAP administration. Glutathionylation is catalyzed by a group of enzymes called the glutathione S-transferase (GST). We found enhanced *Gsta2* expression in montelukast treated liver ([**Figure 3B**](#f3){ref-type="fig"}). However, the mRNA levels of *GSTa1*, *GSTm1*, and *GSTm2* were unaffected ([**Supplementary Figures 4D--F**](#SM1){ref-type="supplementary-material"}).

![Montelukast treatment maintained hepatic GSH level and reduced reactive oxygen species production in APAP treated mice. **(A)** Detection of hepatic glutathione (GSH)/glutathione disulfide (GSSG) level. **(B)** Real-time PCR analysis of hepatic mRNA expression of GSTa2. **(C)** Hepatic H~2~O~2~ level. **(D)** APAP-induced thiobarbituric acid reactive substances (TBARS) level. Data are mean ± SEM, *n* = 5 for saline groups, *n* = 7 for APAP groups, \**p* \< 0.05 , \*\*p \< 0.01.](fphar-10-01070-g003){#f3}

Montelukast Decreased ROS Levels in Mice {#s3_5}
----------------------------------------

Hepatic GSH depletion accumulates APAP metabolites covalently bound to protein, which cause oxidative stress and lipid peroxidation ([@B34]). We evaluated the H~2~O~2~ and TBARS level in mice treated with saline or APAP. We found that APAP greatly increased hepatic H~2~O~2~ and TBARS level in both vehicle and montelukast-treated mice ([**Figures 3C, D**](#f3){ref-type="fig"}). However, montelukast decreased both hepatic H~2~O~2~ and TBARS level compared with vehicle-treated mice ([**Figures 3C, D**](#f3){ref-type="fig"}).

Pharmacological Inhibition of Cysltr1 by Montelukast Prevented Acetaminophen-Induced Liver Inflammation and JNK Activation {#s3_6}
--------------------------------------------------------------------------------------------------------------------------

With overdoses of APAP, hepatic GSH depletion resulted in APAP metabolites covalently bound to protein, which further exacerbates hepatic toxicity by causing inflammatory responses ([@B29]). In our study, levels of the inflammatory cytokines, including *Mcp-1*, *TNF-α*, *Il-6*, and *Il-18*, were increased by APAP administration as expected ([**Figures 4A--D**](#f4){ref-type="fig"}). Montelukast administration alleviated APAP-induced inflammation ([**Figures 4A--D**](#f4){ref-type="fig"}). The phosphorylation of JNK1/2 and ERK1/2, mediators of inflammation, were increased by APAP overdosage ([@B2]). Montelukast suppressed the phosphorylation levels of JNK1/2 after APAP administration ([**Figures 4E, F**](#f4){ref-type="fig"}). Meanwhile, pharmacological inhibition of Cysltr1 slightly inhibited ERK1/2 activation in APAP-treated groups ([**Figures 4E, G**](#f4){ref-type="fig"}).

![Pharmacological inhibition of cysltr1 decrease APAP-induced hepatic inflammation. **(A**--**D)** Real-time PCR analysis of hepatic inflammatory cytokine genes expression, *n* = 5 for saline groups, *n* = 7 for APAP groups. **(E)** Western blotting analysis ERK and JNK phosphorylation. **(F** and **G)** Quantification of phosphorylated JNK to total JNK and phosphorylated ERK to total ERK. Data are mean ± SEM, *n* = 3 for each groups, \**p* \< 0.05, \*\*p \< 0.01. Experiments were repeated three times with similar results.](fphar-10-01070-g004){#f4}

Pharmacological Inhibition of Cysltr1 Protects Mouse Primary Hepatocytes From APAP-Induced Cell Death. {#s3_7}
------------------------------------------------------------------------------------------------------

To further confirm the protective role of montelukast in APAP-induced hepatotoxicity, primary hepatocytes were isolated and pretreated with montelukast 1 h before APAP administration. APAP treatment remarkably increased cytotoxicity as expected ([**Figures 5A, B**](#f5){ref-type="fig"}). Montelukast decreased APAP-induced LDH released at concentrations of 5 and 10 μM ([**Supplementary Figure 5A**](#SM1){ref-type="supplementary-material"}). It seems that montelukast has little effect on the expression of Cysltr1 ([**Supplementary Figure 5B**](#SM1){ref-type="supplementary-material"}). However, montelukast dramatically reversed APAP-induced mitochondrial membrane potential decreasing ([**Figure 5C**](#f5){ref-type="fig"}). Zafirlukast, another kind of Cysltr1 antagonist, also improved APAP-induced hepatocyte death ([**Supplementary Figures 6A, B**](#SM1){ref-type="supplementary-material"}). Moreover, montelukast inhibited LTD~4~, a Cystlr1 agonist, induced hepatocytes damage ([**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}), and thus partly improved APAP-induced hepatotoxicity.

![Montelukast inhibit APAP-induced cell damage. Primary hepatocytes were pretreated with montelukast (5 μM) or vehicle (DMSO) 1 h before APAP (2.5 mM) administration. **(A)** Representative morphological images of primary hepatocytes treated with APAP for 24 h. **(B)** Quantification of LDH released into the culture medium of primary hepatocyte after treatment with 2.5 mM of APAP for 24 h. Data are mean ± SEM, *n* = 3 for each group, \*\**p* \< 0.01. **(C)** Primary hepatocytes were incubated with 5 mg/l JC-1 dye for 30 min at 37°C in the dark and washed twice with the dye buffer. Then, the cells were quickly subjected to a fluorescence microscope for captured red or green fluorescence. Experiments were repeated three times with similar results.](fphar-10-01070-g005){#f5}

Discussion {#s4}
==========

In this study, we showed that inhibition of Cysltr1 protected mice against APAP-induced liver damage. Montelukast postadministration inhibited APAP-induced hepatic oxidative stress and necrosis. Mechanistically, inhibition of Cysltr1 in APAP-treated mice induced the expression of *GSTa2*, which promotes NAPQI detoxification. Compared to the vehicle group, these protective effects were also associated with higher hepatic GSH/GSSG ratio and lower oxidative stress and JNK activity in montelukast-treated group. Montelukast administration also inhibited the inflammatory response with APAP overdose.

Phase II enzymes eliminate most APAP and protect livers from toxicity. The majority of APAP is metabolized by UGT and SULT, then excreted in the urine ([@B32]). Upregulated of UGT and SULT would be helpful to prevent toxicity of APAP overdosage ([@B32]). However, montelukast did not alter the expression of *Ugt1a1* and *Sult2a1* in our study. Phase I metabolic enzymes and transporters also remained unchanged.

Our results showed that protective effect of montelukast in APAP-induced liver damage was associated with an increased level of hepatic GSH, which was thought to accumulate phase I metabolites detoxification. Glutathionylation is catalyzed by a group of enzymes called the GST. Gstm-null mice are found to be resistant to APAP ([@B1]). Upregulation of Gsta is also thought to prevent APAP-induced liver failure ([@B7]; [@B13]). We also showed that montelukast increased *GSTa2* expression after APAP administration, which may improve APAP-induced hepatotoxicity.

Recent studies have shown that montelukast has effects of antioxidant and anti-inflammation in various experimental models ([@B8]; [@B43]; [@B23]). Pharmacological inhibition of Cysltr1 protected aluminum-overload-induced liver injury through PI3K/AKT/mTOR pathway ([@B18]). At overdoses of APAP administration, hepatic GSH was depleted and APAP metabolites covalently bound to protein, which further exacerbates hepatic toxicity by triggering oxidative stress and JNK activation ([@B29]). Inhibition of Cysltr1 by montelukast treatment prevented APAP-induced oxidative stress and JNK activation. Activation of JNK mediates hepatocyte necrosis and trigger inflammation in APAP-induced liver injury model ([@B20]; [@B44]). Several studies suggested that inflammation plays a role in hepatocyte necrosis and is thought to promote liver injury ([@B17]). The decreased activity of JNK and inflammation may contribute to protective effect of montelukast in APAP overdose model.

Studies have reported upregulation of 5-LO pathway in APAP-induced liver injury ([@B41]). Activation of the 5-LO pathway leads to the formation of leukotrienes from arachidonic acid ([@B47]). Leukotrienes are thought to be involved in the production of inflammation and lead to liver injury ([@B38]; [@B21]; [@B31]). We also found LTD~4~-induced hepatocytes injury by promoting LDH released and decreasing mitochondrial membrane potential ([**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}). Knockout or inhibition of 5-LO could prevent APAP-induced liver inflammation and liver injury ([@B31]; [@B16]). Meanwhile, knockout or inhibition of leukotriene receptors is an effective way to treat tissue damage caused by leukotrienes ([@B4]). Several leukotriene receptors are identified. They are Blt1, Blt2, Cysltr1, Cysltr2, and Cysltr3. Functional consequences of Cysltr3 activation are not well defined ([@B10]). Although it has been reported that blocking Blt1 signaling protected APAP-induced hepatotoxicity through preventing excessive accumulation of hepatic neutrophils ([@B25]), Blt1 receptor antagonists have no further development ([@B10]). Montelukast inhibited LTD~4~-induced hepatocytes damage ([**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}) and thus partly improved APAP-induced hepatotoxicity. Therefore, montelukast administration may be a strategy for inhibiting APAP-induced liver injury.

It was attractive that APAP promoted Cysltr1 expression both *in vivo* and *in vitro*. The expression of Cysltr1 was significantly induced in the hepatic ischemia--reperfusion injury and aluminum-overload-induced liver injury ([@B45]; [@B18]). The elevated expression of Cysltr1 has been shown to participate the pathological progress of these diseases. In our study, we also found that Cysltr1 expression was higher in model of APAP-overdose-induced liver injury than the saline group. Blocking Cysltr1 by montelukast-alleviated APAP overdose caused oxidative stress and inflammation. *In vitro*, it was reported that TNF-α, an activator of necrosis, could stimulate Cysltr1 expression in human bronchi and thus promotes hyper-responsiveness ([@B22]). We also found that APAP upregulated Cysltr1 in primary hepatocytes, and it thereby enlarged hepatotoxicity. Future study is needed to study the mechanism of Cysltr1 upregulation under APAP overdose.

N-acetylcysteine (NAC) is thought to be useful in the management of APAP-induced liver injury ([@B5]). In APAP-treated liver, NAC is deacetylated to form L-cysteine, an essential amino acid for the synthesis of GSH ([@B40]). One report compared the therapeutic effects of NAC and montelukast on APAP-induced hepatotoxicity and found that montelukast had better therapeutic effect than NAC did ([@B19]). However, they did not explain the mechanism of montelukast administration in APAP-induced hepatic damage. We observed an increased level of liver GSH/GSSG level, a reduced level of oxidative stress, JNK phosphorylation, and a decreased level of inflammation. These results will elucidate the protective mechanism of montelukast on APAP-induced liver injury. In the future, the prophylactic effect of montelukast should be further evaluated in APAP-induced liver damage.

In summary, the present study demonstrated that pharmacological inhibition of Cysltr1 by montelukast conferred resistance to APAP-induced hepatotoxicity. The protective effect of montelukast was, at least in part, attributed to upregulation of hepatic GSH/GSSG, suppression of oxidative stress and JNK pathway. Targeted inhibition of the Cysltr1 by montelukast may be a potential treatment strategy in APAP-induced hepatotoxicity.
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